These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29185862)

  • 1. The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans.
    Crooke ST; Baker BF; Pham NC; Hughes SG; Kwoh TJ; Cai D; Tsimikas S; Geary RS; Bhanot S
    Nucleic Acid Ther; 2018 Feb; 28(1):10-22. PubMed ID: 29185862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.
    Crooke ST; Baker BF; Witztum JL; Kwoh TJ; Pham NC; Salgado N; McEvoy BW; Cheng W; Hughes SG; Bhanot S; Geary RS
    Nucleic Acid Ther; 2017 Jun; 27(3):121-129. PubMed ID: 28145801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Tolerability of GalNAc
    Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
    Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in the Tolerability Profile of 2'-
    Partridge W; Xia S; Kwoh TJ; Bhanot S; Geary RS; Baker BF
    Nucleic Acid Ther; 2021 Dec; 31(6):417-426. PubMed ID: 34242101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Assessment of Phase 2 Data on GalNAc
    Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
    Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates.
    Slingsby MHL; Vijey P; Tsai IT; Roweth H; Couldwell G; Wilkie AR; Gaus H; Goolsby JM; Okazaki R; Terkovich BE; Semple JW; Thon JN; Henry SP; Narayanan P; Italiano JE
    Haematologica; 2022 Feb; 107(2):519-531. PubMed ID: 33567808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
    Kim TW; Kim KS; Seo JW; Park SY; Henry SP
    J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-
    Pirie E; Cauntay P; Fu W; Ray S; Pan C; Lusis AJ; Hsiao J; Burel SA; Narayanan P; Crooke RM; Lee RG
    Nucleic Acid Ther; 2019 Oct; 29(5):266-277. PubMed ID: 31368839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor XI antisense oligonucleotide for prevention of venous thrombosis.
    Büller HR; Bethune C; Bhanot S; Gailani D; Monia BP; Raskob GE; Segers A; Verhamme P; Weitz JI;
    N Engl J Med; 2015 Jan; 372(3):232-40. PubMed ID: 25482425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events.
    Partridge W; Burel SA; Ferng A; Xia S; Kwoh TJ; Henry SP; Baker BF
    Clin Transl Sci; 2023 Apr; 16(4):575-580. PubMed ID: 36631935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.
    Henry SP; Narayanan P; Shen L; Bhanot S; Younis HS; Burel SA
    Nucleic Acid Ther; 2017 Aug; 27(4):197-208. PubMed ID: 28541820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects.
    Yu RZ; Gunawan R; Geary RS; Hughes SG; Henry SP; Wang Y
    Nucleic Acid Ther; 2017 Oct; 27(5):285-294. PubMed ID: 28799823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
    Billioud G; Kruse RL; Carrillo M; Whitten-Bauer C; Gao D; Kim A; Chen L; McCaleb ML; Crosby JR; Hamatake R; Hong Z; Garaigorta U; Swayze E; Bissig KD; Wieland S
    J Hepatol; 2016 Apr; 64(4):781-9. PubMed ID: 26658683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials.
    Rovin BH; Dooley MA; Radhakrishnan J; Ginzler EM; Forrester TD; Anderson PW
    Lupus; 2016 Dec; 25(14):1597-1601. PubMed ID: 27220348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
    Koller E; Propp S; Zhang H; Zhao C; Xiao X; Chang M; Hirsch SA; Shepard PJ; Koo S; Murphy C; Glazer RI; Dean NM
    Cancer Res; 2006 Feb; 66(4):2059-66. PubMed ID: 16489005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
    Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.
    Hirschberg R; Kopple J; Lipsett P; Benjamin E; Minei J; Albertson T; Munger M; Metzler M; Zaloga G; Murray M; Lowry S; Conger J; McKeown W; O'shea M; Baughman R; Wood K; Haupt M; Kaiser R; Simms H; Warnock D; Summer W; Hintz R; Myers B; Haenftling K; Capra W
    Kidney Int; 1999 Jun; 55(6):2423-32. PubMed ID: 10354291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.